Antibiotic Resistance

Finding the right sequence of drugs

Rapidly switching between similar antibiotics may help to slow down the evolution of resistance.

Anh Huynh and Kevin B Wood

In order to survive, many living organisms need to be able to adapt to their ever-changing environment. These past experiences shape the behavior of creatures big and small – from mutations in single genes to neurological changes that underlie memory formation in primates.

There is substantial evidence that environmental history affects how bacteria respond to antibiotics (Barbosa et al., 2019; Card et al., 2019; Nichol et al., 2019; Santos-Lopez et al., 2019; Yen and Papin, 2017). This has led researchers to suggest that switching between drugs over time could help slow down antibiotic resistance, as this will force the bacteria into a scenario where their existing solutions (resistance to the current drug) cannot protect them from tomorrow’s problem (a new drug). However, this method has led to mixed results (Abel zur Wiesch et al., 2014; Imamovic et al., 2018), and optimizing this approach is challenging, in part because it is unclear which features of the antibiotic sequence are the most important and guarantee the best results.

Now, in eLife, Hinrich Schulenburg (University of Kiel and Max Planck Institute for Evolutionary Biology) and colleagues – including Aditi Batra and Roderich Roemhild as joint first authors – report the results of experiments on the multi-drug resistant bacteria Pseudomonas aeruginosa (Batra et al., 2021). The team (who are based in Austria and Germany) exposed the bacteria to various sequences of three antibiotics that belong to commonly used classes of drugs: one class targets the ribosome, one targets DNA gyrase, and one targets the cell wall. In some cases, three drugs from different classes were used (that is, a heterogeneous sequence), and in some cases all three drugs belonged to the same class (a homogenous sequence). Batra et al. also varied the temporal properties of each sequence by switching between the drugs rapidly, slowly, or in a random order. The growth rate, phenotypic resistance levels and population genetics of the evolved populations were then analyzed to determine which sequences of drugs were the most effective at eliminating the bacteria (Figure 1A).

In addition to these experimental parameters, the impact of different antibiotic sequences could also depend on how the population biologically responds to consecutive drug exposures (Figure 1B). For example, the genetic changes bacteria evolve in response to one antibiotic can lead to collateral effects that increase the population’s resistance or sensitivity to another drug. Because collateral resistance occurs more frequently between drugs of the same class, heterogeneous sequences of antibiotics are thought to be more effective at
eliminating bacteria (Imamovic and Sommer, 2013; Lázár et al., 2013; Maltas and Wood, 2019; Pál et al., 2015; Lázár et al., 2014). Treatment with unrelated drugs has also been shown to favor negative hysteresis, which is when short-term physiological changes induced by one antibiotic enhance susceptibility towards another. Indeed, a recent study found that rapid switching between antibiotics from different classes promoted extinction of bacterial populations, even when the drugs were used at sub-inhibitory levels (Roemhild et al., 2018).

However, Batra et al. found that homogenous sequences of beta-lactams (a class of antibiotics that target the cell wall) were surprisingly more effective at clearing bacteria. The experiments also revealed that extinction tended to occur early in the treatment and was less effective when drugs were switched more slowly. A particular heterogeneous set of drugs also tended not to eliminate bacteria, indicating that heterogeneity, alone, does not guarantee success.

So, what are the important characteristics of a ‘good’ antibiotic sequence? To answer this question, Batra et al. used a common class of statistical models to probe for signatures of successful sequences. They found that extinction was strongly favored by two biological properties — low rates of spontaneous resistance and low levels of collateral resistance — and was also enhanced when switching between drugs was fast or random. This suggests that although the findings of Batra et al. contradict the proposed benefits of using unrelated drugs, they still validate a portion of the underlying logic: using antibiotics with strong collateral effects and

---

**Figure 1.** Experimental and biological features of effective drug sequences. (A) Batra et al. applied different sequences of antibiotics to 756 populations of *P. aeruginosa* (top panel). The bacteria were treated with either a single drug (monotherapy; row 1), or three antibiotics which were switched rapidly (row 2), slowly (row 3) or in a random order (row 4): the three drugs were either from the same class (homogeneous) or from different classes (heterogeneous). This experiment revealed that fast (blue line) and random (green line) switching between three homogeneous beta-lactam drugs reduced bacteria growth and resulted in higher levels of extinction (bottom graph). (B) The effects of the different sequences are also impacted by biological features. (Top panel) When sensitive bacteria (shown in purple) are treated with the first drug, some cells will evolve genetic changes that make them resistant to the antibiotic treatment (shown in green). These evolutionary changes can lead to collateral effects that make the bacteria less (top arrow), equally (middle arrow) or more (bottom arrow) resistant to the second drug. (Bottom panel) Treatment with the first drug may also lead to negative hysteresis, when short-term physiological changes enhance the bacteria’s response to the second drug (right), leading to more cell death in the population compared to bacteria not pre-treated with the first drug (left).

Image credit: Anh Huynh.
Finding the right sequence of drugs

Antibiotic Resistance

Insight

Pathogens

Bonhoeffer S. 2014. Cycling empirical antibiotic sequential therapy with only evolutionary solutions.

Niemann S, Schulenburg H. 2021. High potency of 7554/eLife.51481 University of Michigan, Ann Arbor, United States Anh Huynh

Hysteresis enhances the impact of sequence therapy. It just turns out, however, that drugs with these characteristics are not always from different classes.

This study offers insight into how past antibiotic exposure shapes the response of bacterial populations to new challenges. In doing so, it provides a roadmap for future studies investigating how even the simplest organisms harbor signatures of past challenges and potential evolutionary solutions.

Anh Huynh is in the Department of Biophysics, University of Michigan, Ann Arbor, United States

https://orcid.org/0000-0001-8891-4234

Kevin B Wood is in the Department of Biophysics and Department of Physics, University of Michigan, Ann Arbor, United States

kbwood@umich.edu

https://orcid.org/0000-0002-0985-7401

Competing interests: The authors declare that no competing interests exist.

Published 09 September 2021

References

Abel zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S. 2014. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLOS Pathogens 10:e1004225. DOI: https://doi.org/10.1371/journal.ppat.1004225, PMID: 24968123

Barbosa C, Römheld R, Rosenstiel P, Schulenburg H. 2019. Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen Pseudomonas aeruginosa. eLife 8:e51481. DOI: https://doi.org/10.7554/elife.51481, PMID: 31658946

Batra A, Roemhild R, Rousseau E, Franzenburg S, Niemann S, Schulenburg H. 2021. High potency of sequential therapy with only β-lactam antibiotics. eLife 10:e68876. DOI: https://doi.org/10.7554/elife.68876, PMID: 34318749

Card KJ, LaBar T, Gomez JB, Lenski RE. 2019. Historical contingency in the evolution of antibiotic resistance after decades of relaxed selection. PLOS Biology 17:e300397. DOI: https://doi.org/10.1371/journal.pbio.300397, PMID: 31644535

Imamovic L, Ellabaan MMH, Dantas Machado AM, Citterio L, Wulf T, Molin S, Krogh Johansen H, Sommer MOA. 2018. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. Cell 172:121–134. DOI: https://doi.org/10.1016/j.cell.2017.12.012, PMID: 29307490

Imamovic L, Sommer MO. 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Science Translational Medicine 5:204ra132. DOI: https://doi.org/10.1126/scitranslmed.3006669, PMID: 24068739

Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrytyn M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. 2013. Bacterial evolution of antibiotic hypersensitivity. Molecular Systems Biology 9:700. DOI: https://doi.org/10.1038/msb.2013.57, PMID: 24169403

Lázár V, Nagy I, Spohn R, Csörgő B, Györkei Á, Nyerges Á, Horváth B, Vörös A, Busa-Fekete R, Hrytyn M, Bogos B, Méhi O, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. 2014. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nature Communications 5:4352. DOI: https://doi.org/10.1038/ncomms5392, PMID: 25009950

Maltas J, Wood KB. 2019. Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance. PLOS Biology 17:e3000515. DOI: https://doi.org/10.1371/journal.pbio.3000515, PMID: 31652256

Nichol D, Rutter J, Bryant C, Hujer AM, Lek S, Adams MD, Jeavons P, Anderson ARA, Bonomo RA, Scott JG. 2019. Antibiotic collateral sensitivity is contingent on the repeatability of evolution. Nature Communications 10:334. DOI: https://doi.org/10.1038/s41467-018-08098-6

Pál C, Papp B, Lázár V. 2015. Collateral sensitivity of antibiotic-resistant microbes. Trends in Microbiology 23:401–407. DOI: https://doi.org/10.1016/j.tim.2015.02.009, PMID: 25818802

Roemhild R, Gokhale CS, Dirksen P, Blake C, Rosenstiel P, Traulsen A, Andersson DI, Schulenburg H. 2018. Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy. PNAS 115:9767–9772. DOI: https://doi.org/10.1073/pnas.1810041115, PMID: 30209218

Santos-Lopez A, Marshall CW, Scriber MR, Snyder DJ, Cooper VS. 2019. Evolutionary pathways to antibiotic resistance are dependent upon environmental structure and bacterial lifestyle. eLife 8:e47612. DOI: https://doi.org/10.7554/elife.47612, PMID: 31516122

Yen P, Papin JA. 2017. History of antibiotic adaptation influences microbial evolutionary dynamics during subsequent treatment. PLOS Biology 15:e2001586. DOI: https://doi.org/10.1371/journal.pbio.2001586, PMID: 28792497